Urgent

Acute lymphoblastic leukaemia (ALL) - management overview

ALL · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A malignancy of lymphoid precursors, the commonest childhood leukaemia but also seen in adults with poorer outcomes. Treatment uses prolonged multi-phase chemotherapy with CNS-directed therapy, targeted agents for Philadelphia-positive disease, and immunotherapy for relapse.

Red flags

  • CNS involvement (cranial nerve palsy, headache)
  • Tumour lysis syndrome
  • Mediastinal mass with airway/SVC compromise (T-ALL)
  • Neutropenic sepsis
  • Hyperleukocytosis

Assessment

Differential diagnosis

  • Acute myeloid leukaemia
  • Lymphoblastic lymphoma
  • Blast-phase CML
  • Infectious mononucleosis / reactive lymphocytosis
  • Aplastic anaemia
  • Neuroblastoma (children)

Investigations

  • FBC, film and blast count
  • Bone marrow with immunophenotyping (B vs T lineage)
  • Cytogenetics and molecular tests including BCR::ABL1 (Ph+)
  • CSF examination for CNS involvement
  • Tumour lysis labs and coagulation screen
  • Testicular/imaging assessment and HLA typing

Management

  • Recognise and admit urgently with supportive stabilisation
  • Start tumour lysis prophylaxis and treat any sepsis
  • Confirm diagnosis, lineage and genetic subtype including Philadelphia chromosome status
  • Risk-stratify by age, white count, genetics and measurable residual disease
  • Deliver multi-phase therapy: induction, consolidation, CNS-directed therapy, and prolonged maintenance
  • Add a tyrosine kinase inhibitor to chemotherapy for Philadelphia-positive ALL
  • Provide intrathecal chemotherapy +/- cranial irradiation for CNS prophylaxis
  • Monitor measurable residual disease to guide intensification and transplant
  • Use immunotherapy (blinatumomab, inotuzumab) and CAR-T for relapsed/refractory B-ALL
  • Refer high-risk and relapsed disease for allogeneic transplant

Drugs & doses

Induction: vincristine 1.4 mg/m2 IV (cap 2 mg) weekly + corticosteroid (dexamethasone/prednisolone) + asparaginase + anthracycline
Imatinib 400-600 mg PO daily or dasatinib added for Philadelphia-positive ALL
Intrathecal methotrexate for CNS-directed therapy; 6-mercaptopurine + methotrexate maintenance
Blinatumomab IV continuous infusion / tisagenlecleucel CAR-T for relapsed B-ALL

Disposition

Immediate specialist admission; prolonged multidisciplinary protocol therapy; transplant/CAR-T referral for high-risk or relapsed disease.

Complications & pitfalls

  • Tumour lysis syndrome
  • Neutropenic sepsis
  • CNS relapse
  • Asparaginase toxicity (thrombosis, pancreatitis)
  • Treatment-related late effects
  • Relapse

Exam pearls

  • Measurable residual disease is the strongest prognostic marker and steers therapy
  • Philadelphia-positive ALL now responds well to chemotherapy plus a TKI
  • CNS-directed therapy is essential - the CNS is a sanctuary site
  • Immunotherapy and CAR-T have revolutionised relapsed B-ALL
  • Paediatric-inspired protocols improve outcomes in younger adults

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.